These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26494820)

  • 21. [Not Available].
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Nov; 193(45):E1746-E1749. PubMed ID: 34782384
    [No Abstract]   [Full Text] [Related]  

  • 22. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin.
    van Niekerk C; Wallace J; Takata M; Yu R
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30131409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-occlusive Mesenteric Ischemia with Diabetic Ketoacidosis and Lactic Acidosis Following the Administration of a Sodium Glucose Co-transporter 2 Inhibitor.
    Gocho N; Aoki E; Okada C; Omura K; Hirashima T; Suzuki N; Tanaka H; Omori Y
    Intern Med; 2016; 55(13):1755-60. PubMed ID: 27374678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 25. Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin.
    Bonanni FB; Fei P; Fitzpatrick LL
    Surg Obes Relat Dis; 2016 Jan; 12(1):e11-2. PubMed ID: 26686305
    [No Abstract]   [Full Text] [Related]  

  • 26. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.
    Bobart SA; Gleason B; Martinez N; Norris K; Williams SF
    Ann Intern Med; 2016 Oct; 165(7):530-532. PubMed ID: 27699391
    [No Abstract]   [Full Text] [Related]  

  • 28. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
    Qiu R; Balis D; Xie J; Davies MJ; Desai M; Meininger G
    Curr Med Res Opin; 2017 Mar; 33(3):553-562. PubMed ID: 27977934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
    Guthrie R
    Postgrad Med; 2018 Mar; 130(2):149-153. PubMed ID: 29297732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canagliflozin-Associated Acute Pancreatitis.
    Verma R
    Am J Ther; 2016; 23(3):e972-3. PubMed ID: 25187092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
    Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
    J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?
    Abate N; Chandalia M
    Metab Syndr Relat Disord; 2016 Feb; 14(1):1-2. PubMed ID: 26554527
    [No Abstract]   [Full Text] [Related]  

  • 33. Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis.
    Dizon S; Keely EJ; Malcolm J; Arnaout A
    Can J Diabetes; 2017 Oct; 41(5):499-503. PubMed ID: 28797889
    [No Abstract]   [Full Text] [Related]  

  • 34. Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes.
    Kushner P
    Womens Health (Lond); 2016 Jun; 12(3):379-88. PubMed ID: 26928259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney.
    Palmer BF; Clegg DJ; Taylor SI; Weir MR
    J Diabetes Complications; 2016 Aug; 30(6):1162-6. PubMed ID: 27240541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes Drug Receives New Indication.
    Aschenbrenner DS
    Am J Nurs; 2017 Apr; 117(4):24-25. PubMed ID: 28333738
    [No Abstract]   [Full Text] [Related]  

  • 37. An Unusual Case of Metabolic Acidosis: Clinical Case Education.
    Abu-Amer N; Dinour D; Mini S; Beckerman P
    Isr Med Assoc J; 2019 Nov; 21(11):766-768. PubMed ID: 31713370
    [No Abstract]   [Full Text] [Related]  

  • 38. In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis.
    Sfeir JG; Montori VM
    Ann Intern Med; 2016 Jul; 165(2):JC2. PubMed ID: 27429314
    [No Abstract]   [Full Text] [Related]  

  • 39. Letter to the Editor: Comment on "SGLT2 inhibitors may predispose to ketoacidosis" by Taylor S.I., et al.
    Segar L
    J Clin Endocrinol Metab; 2016 Feb; 101(2):L27-8. PubMed ID: 26840113
    [No Abstract]   [Full Text] [Related]  

  • 40. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
    Alba M; Xie J; Fung A; Desai M
    Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.